Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Symlin
Symlin (pramlintide acetate) is an injectable, synthetic analog of the human hormone amylin. It is used in conjunction with insulin in patients with type 1 and type 2 diabetes who have not achieved optimal glucose control despite insulin therapy. Amylin, normally produced by the pancreas alongside insulin, plays a role in regulating postprandial glucose levels by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety, which helps control appetite. Symlin mimics these actions, aiding in better blood sugar management.
For use with insulin to improve glycemic control in adults with type 1 and type 2 diabetes mellitus.
Severe hypoglycemia, especially in type 1 diabetes, can occur within 3 hours after injection. Patients using Symlin with insulin should reduce their insulin dose and eat frequently to avoid hypoglycemia.
Outcome:
Increased risk of severe hypoglycemia
Mechanism:
Synergistic effect on glucose lowering
Outcome:
Masking of hypoglycemia symptoms
Mechanism:
Beta-blockers can block the sympathetic nervous system response to low blood sugar.
Outcome:
Some antibiotics may affect blood sugar levels
Mechanism:
Variable mechanisms
Most likely new formulation: A once-weekly injectable formulation (2026, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of Symlin maintaining its current FDA approval status for the next 5 years.
Amylinomimetic, Antidiabetic Agent
Peptide Hormone Analog